About: Diferenciace, apoptosa a regulace transkripce u buněk zhoubných nádorů

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diferenciace, apoptosa a regulace transkripce u buněk zhoubných nádorů Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Zamer, within Data Space : linked.opendata.cz:8890 associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/domain/vavai/Zamer
Description	Molekulárně biologický a biochemický výzkum bude zaměřen na studium poruch diferenciace a apoptosy nádorových buněk a na deregulaci genové exprese na úrovni transkripce v souvislosti s některými jadernými onkosupresorovými proteiny. Dále budou vyvíjeny m, olekulárně biologické přístupy přispívající ke stanovení diagnózy a určení prognózy karcinomu plic a budou prováděny epidemiologické studie plicního karcinomu., , Molecular biological and biochemical research will be aimed at studies of defects of differentiation and apoptosis in cancer cells. Further, deregulation of gene expression at the transcriptional level will be investigated in the context of function ofso, me nuclear oncosuppressor proteins. Molecular approaches will be developed in order to improve diagnosis and prognostic estimations in lung carcinoma. Finally, epidemiology studies of lung carcinoma will be carried out., , (en)
Title	Diferenciace, apoptosa a regulace transkripce u buněk zhoubných nádorů Differentiation, apoptosis and transcriptional regulation in cancer cells (en)
http://linked.open...kovaStatniPodpora	http://linked.opendata.cz/resource/domain/vavai/zamer/MZ00000064211/celkovaStatniPodpora
http://linked.open...ez/celkoveNaklady	http://linked.opendata.cz/resource/domain/vavai/zamer/MZ00000064211/celkoveNaklady
http://linked.open...datumDodatniDoRIV	2006-09-11 (xsd:date)
http://linked.open...vavai/cez/dodavka	http://linked.opendata.cz/resource/domain/vavai/dodavka/CEZ%2F2005%2FMZ0%2FMZ0500%2FU%2FN%2F2%3A2
http://linked.open...ez/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...in/vavai/cez/faze	33156047
http://linked.open...ai/cez/hlavniObor	FD - Onkologie a hematologie
http://linked.open...vai/cez/hodnoceni	V - Vynikající výsledky (s mezinárodním významem apod.). Zároveň byly splněny cíle a předpokládané výsledky uvedené ve smlouvě / rozhodnutí o poskytnutí podpory.
http://linked.open.../cez/kategorieVaV	NV - Aplikovaný výzkum s výjimkou průmyslového výzkumu (tzv. %22neprůmyslový výzkum%22)
http://linked.open.../cez/klicovaSlova	differentiation,apoptosis,transcription,caspases tumor suppressors,lung carcinoma,colon carcinoma, (en)
http://linked.open...icUkonceniPodpory	12 (xsd:int)
http://linked.open...icZahajeniPodpory	1 (xsd:int)
http://linked.open...cez/partnerHlavni	Fakultní nemocnice s poliklinikou na Bulovce
http://linked.open...z/poceVysledkuRIV	45 (xsd:int)
http://linked.open...inujicichPrijemcu	0 (xsd:int)
http://linked.open...cez/pocetPrijemcu	1 (xsd:int)
http://linked.open...ocetSpoluPrijemcu	0 (xsd:int)
http://linked.open...enychVysledkuVRIV	45 (xsd:int)
http://linked.open.../vavai/cez/resort	Ministry of Health
http://linked.open...okUkonceniPodpory	2004
http://linked.open...okZahajeniPodpory	2000
http://linked.open...iciPoslednihoRoku	2005
http://linked.open...atUdajeProjZameru	2005
http://linked.open...usZobrazovaneFaze	DUU
http://linked.open...n/vavai/cez/zamer	Z - Výzkumný záměr financovaný ze státního rozpočtu
http://linked.open...sledkuDodavatelem	New knowledge concerning particularly the malignant melanoma, non-smallcell carconoma of lungs, as well as risk and protective factors of carcinoma in females, was obtained. (en) Byly získány nové poznatky zejména o maligním melanomu, embrynálním karcinomu a nemalobuněčném karcinomu plic, a o rizikových a protektivních faktorech plicní rakoviny u žen. V klinice potvrzena účinnost chemoradioterapie u Ca plic. (cs)
http://linked.open...cez/zivotniCyklus	ZBBBKU
is http://linked.open...n/vavai/riv/zamer of	Differences in the expression levels of transcripts encoding the regulatory and effector components of the apoptosome pathway in non-small cell lung carcinoma and the lung Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer Současné možnosti léčby CHOPN Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis A case-control study of lifestyle and lung cancer associations by histological types. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Randomized phase III trial comparing bexarotene (L106949)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: Biologická léčba karcinomu plic Degradační produkty kolagenu a elastinu jako možné ukazatele aktivity sklerodermie Léčba karcinomu plic Biologická léčba nemalobuněčného karcinomu plic Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer Cetuximab plus chemotherapy in patiens with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues. Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Avanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). Journal of Thoracic Oncology First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study Interdisciplinární konsensus pro prediktivní vyšetřování aktivačních mutací receptoru pro epidermální růstový faktor (EGFR) u nemalobuněčného karcinomu plic Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis Expression of apoptosome pathway-related transcripts in non-small cell lung cancer Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Enzymology of tumor cell apoptosis Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer: A randomized phase II study Development of Real-Time RT-PCR assays for expression studies of apoptosis-controlling genes Proteases and antiproteases in health and disease - a review III. Cysteine proteases and natural inhibitors Surgical treatment of bronchopulmonary carcinoid Biologie bronchogenního karcinomu BIBF 1120 for the therapy of non-small cell lung cancer Bronchogenic carcinoma - treatment Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer Hodnocení a klinická aplikace vyšetření difuzní kapacity plic Plicní rakovina u žen Lung cancer in women Surgical treatment of the primary pulmonary hypertension - lung transplantation Bronchial carcinoid tumors: long-term outcome after surgery Repression of the melanocyte-specific promoter of the microphthalmia-associated transcription factor by the adenoviral E1A 12S oncoprotein
is http://linked.open...omain/vavai/zamer of	http://linked.opendata.cz/resource/domain/vavai/cez/ucast/MZ00000064211/2000/ico%3A00064211 http://linked.opendata.cz/resource/domain/vavai/cez/ucast/MZ00000064211/2001/ico%3A00064211 http://linked.opendata.cz/resource/domain/vavai/cez/ucast/MZ00000064211/2002/ico%3A00064211 http://linked.opendata.cz/resource/domain/vavai/cez/ucast/MZ00000064211/2003/ico%3A00064211 http://linked.opendata.cz/resource/domain/vavai/cez/ucast/MZ00000064211/2004/ico%3A00064211 http://linked.opendata.cz/resource/domain/vavai/cez/ucast/MZ00000064211/2005/ico%3A00064211
is http://linked.open...n/vavai/cez/zamer of	http://linked.opendata.cz/resource/domain/vavai/cez/financovani/MZ00000064211/2000 http://linked.opendata.cz/resource/domain/vavai/cez/financovani/MZ00000064211/2001 http://linked.opendata.cz/resource/domain/vavai/cez/financovani/MZ00000064211/2002 http://linked.opendata.cz/resource/domain/vavai/cez/financovani/MZ00000064211/2003 http://linked.opendata.cz/resource/domain/vavai/cez/financovani/MZ00000064211/2004

Faceted Search & Find service v1.16.121 as of Mar 31 2025

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Mar 31 2025, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software